These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 11954048)
1. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Carta AR; Pinna A; Cauli O; Morelli M Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048 [TBL] [Abstract][Full Text] [Related]
2. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Pinna A; Fenu S; Morelli M Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438 [TBL] [Abstract][Full Text] [Related]
3. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359 [TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Carta AR; Pinna A; Tronci E; Morelli M Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798 [TBL] [Abstract][Full Text] [Related]
6. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Carta AR; Tronci E; Pinna A; Morelli M Eur J Neurosci; 2005 Mar; 21(5):1196-204. PubMed ID: 15813929 [TBL] [Abstract][Full Text] [Related]
7. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. St-Hilaire M; Landry E; Lévesque D; Rouillard C Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973 [TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Cenci MA; Lee CS; Björklund A Eur J Neurosci; 1998 Aug; 10(8):2694-706. PubMed ID: 9767399 [TBL] [Abstract][Full Text] [Related]
9. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422 [TBL] [Abstract][Full Text] [Related]
10. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103 [TBL] [Abstract][Full Text] [Related]
12. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons. Van De Witte SV; Groenewegen HJ; Voorn P Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728 [TBL] [Abstract][Full Text] [Related]
13. Gene expression of the GAD67 and GAD65 isoforms of glutamate decarboxylase is differentially altered in subpopulations of striatal neurons in adult rats lesioned with 6-OHDA as neonates. Laprade N; Soghomonian JJ Synapse; 1999 Jul; 33(1):36-48. PubMed ID: 10380849 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. Tomiyama M; Kimura T; Maeda T; Tanaka H; Kannari K; Baba M Synapse; 2004 Jun; 52(3):218-22. PubMed ID: 15065221 [TBL] [Abstract][Full Text] [Related]
15. Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model. Bacci JJ; Salin P; Kerkerian-Le Goff L Synapse; 2002 Dec; 46(4):224-34. PubMed ID: 12373737 [TBL] [Abstract][Full Text] [Related]
16. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115 [TBL] [Abstract][Full Text] [Related]
17. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Morelli M; Pinna A Neurol Sci; 2001 Feb; 22(1):71-2. PubMed ID: 11487207 [TBL] [Abstract][Full Text] [Related]
18. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats. Glavan G Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798 [TBL] [Abstract][Full Text] [Related]
19. Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Pinna A; Fenu S; Morelli M Synapse; 2001 Mar; 39(2):233-238. PubMed ID: 11169767 [TBL] [Abstract][Full Text] [Related]
20. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]